Growth hormone effects on hypertrophic scar formation: A randomized controlled trial of 62 burned children

Gisele V. De Oliveira, Arthur P. Sanford, Kevin D. Murphy, Hermes M. De Oliveira, Judy P. Wilkins, Xiaowu Wu, Hal K. Hawkins, Gregory Kitten, David L. Chinkes, Robert E. Barrow, David Herndon

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The hypercatabolism after massive pediatric burns has been effectively treated with recombinant human growth hormone, an anabolic agent that stimulates protein synthesis and abrogates growth arrest. While experimental studies have shown increased potential for fibrosis induced by growth hormone therapy, adverse effects on human scars have not been investigated. Our aim was to evaluate hypertrophic scar formation in 62 patients randomized to receive injections of 0.05mg/kg/day of recombinant human growth hormone or placebo, from discharge until 1 year after burn. Scar scales were used to evaluate scar-severity at discharge, 6, 9, 12, and 18-24 months after burn, by three observers blinded to treatment. Computer-assisted planimetry allowed quantification of percentage of hypertrophic scar formation. Types I and III collagens were localized and quantified in scars and normal skin of patients from both groups, using immunohistochemistry with confocal laser microscopy analysis. Insulin-like growth factor-1 blood levels helped assess compliance. Statistical analysis showed that scar hypertrophy significantly increased from 6 to 12 months after injury in both groups, while decreasing at 18-24 months postburn. Types I and III collagens were statistically increased in the reticular layer of scars from both groups when compared to paired normal skin. Insulin-like growth factor-1 was significantly increased in the recombinant human growth factor-treated group. No differences were seen when recombinant human growth factor and control groups were compared using the scar scales, planimetry, or immunohistochemistry. We concluded that recombinant human growth hormone therapy did not adversely affect scar formation and should not contraindicate the administration of recombinant human growth hormone as a therapeutic approach to severely burned children.

Original languageEnglish (US)
Pages (from-to)404-411
Number of pages8
JournalWound Repair and Regeneration
Volume12
Issue number4
DOIs
StatePublished - Jul 2004

Fingerprint

Hypertrophic Cicatrix
Growth Hormone
Cicatrix
Randomized Controlled Trials
Human Growth Hormone
Collagen Type III
Somatomedins
Collagen Type I
Confocal Microscopy
Intercellular Signaling Peptides and Proteins
Immunohistochemistry
Anabolic Agents
Skin
Therapeutics
Burns
Hypertrophy
Compliance
Fibrosis
Placebos
Pediatrics

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

De Oliveira, G. V., Sanford, A. P., Murphy, K. D., De Oliveira, H. M., Wilkins, J. P., Wu, X., ... Herndon, D. (2004). Growth hormone effects on hypertrophic scar formation: A randomized controlled trial of 62 burned children. Wound Repair and Regeneration, 12(4), 404-411. https://doi.org/10.1111/j.1067-1927.2004.012407.x

Growth hormone effects on hypertrophic scar formation : A randomized controlled trial of 62 burned children. / De Oliveira, Gisele V.; Sanford, Arthur P.; Murphy, Kevin D.; De Oliveira, Hermes M.; Wilkins, Judy P.; Wu, Xiaowu; Hawkins, Hal K.; Kitten, Gregory; Chinkes, David L.; Barrow, Robert E.; Herndon, David.

In: Wound Repair and Regeneration, Vol. 12, No. 4, 07.2004, p. 404-411.

Research output: Contribution to journalArticle

De Oliveira, GV, Sanford, AP, Murphy, KD, De Oliveira, HM, Wilkins, JP, Wu, X, Hawkins, HK, Kitten, G, Chinkes, DL, Barrow, RE & Herndon, D 2004, 'Growth hormone effects on hypertrophic scar formation: A randomized controlled trial of 62 burned children', Wound Repair and Regeneration, vol. 12, no. 4, pp. 404-411. https://doi.org/10.1111/j.1067-1927.2004.012407.x
De Oliveira, Gisele V. ; Sanford, Arthur P. ; Murphy, Kevin D. ; De Oliveira, Hermes M. ; Wilkins, Judy P. ; Wu, Xiaowu ; Hawkins, Hal K. ; Kitten, Gregory ; Chinkes, David L. ; Barrow, Robert E. ; Herndon, David. / Growth hormone effects on hypertrophic scar formation : A randomized controlled trial of 62 burned children. In: Wound Repair and Regeneration. 2004 ; Vol. 12, No. 4. pp. 404-411.
@article{dfab40f543074c9db1d9fb54dede2dbe,
title = "Growth hormone effects on hypertrophic scar formation: A randomized controlled trial of 62 burned children",
abstract = "The hypercatabolism after massive pediatric burns has been effectively treated with recombinant human growth hormone, an anabolic agent that stimulates protein synthesis and abrogates growth arrest. While experimental studies have shown increased potential for fibrosis induced by growth hormone therapy, adverse effects on human scars have not been investigated. Our aim was to evaluate hypertrophic scar formation in 62 patients randomized to receive injections of 0.05mg/kg/day of recombinant human growth hormone or placebo, from discharge until 1 year after burn. Scar scales were used to evaluate scar-severity at discharge, 6, 9, 12, and 18-24 months after burn, by three observers blinded to treatment. Computer-assisted planimetry allowed quantification of percentage of hypertrophic scar formation. Types I and III collagens were localized and quantified in scars and normal skin of patients from both groups, using immunohistochemistry with confocal laser microscopy analysis. Insulin-like growth factor-1 blood levels helped assess compliance. Statistical analysis showed that scar hypertrophy significantly increased from 6 to 12 months after injury in both groups, while decreasing at 18-24 months postburn. Types I and III collagens were statistically increased in the reticular layer of scars from both groups when compared to paired normal skin. Insulin-like growth factor-1 was significantly increased in the recombinant human growth factor-treated group. No differences were seen when recombinant human growth factor and control groups were compared using the scar scales, planimetry, or immunohistochemistry. We concluded that recombinant human growth hormone therapy did not adversely affect scar formation and should not contraindicate the administration of recombinant human growth hormone as a therapeutic approach to severely burned children.",
author = "{De Oliveira}, {Gisele V.} and Sanford, {Arthur P.} and Murphy, {Kevin D.} and {De Oliveira}, {Hermes M.} and Wilkins, {Judy P.} and Xiaowu Wu and Hawkins, {Hal K.} and Gregory Kitten and Chinkes, {David L.} and Barrow, {Robert E.} and David Herndon",
year = "2004",
month = "7",
doi = "10.1111/j.1067-1927.2004.012407.x",
language = "English (US)",
volume = "12",
pages = "404--411",
journal = "Wound Repair and Regeneration",
issn = "1067-1927",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Growth hormone effects on hypertrophic scar formation

T2 - A randomized controlled trial of 62 burned children

AU - De Oliveira, Gisele V.

AU - Sanford, Arthur P.

AU - Murphy, Kevin D.

AU - De Oliveira, Hermes M.

AU - Wilkins, Judy P.

AU - Wu, Xiaowu

AU - Hawkins, Hal K.

AU - Kitten, Gregory

AU - Chinkes, David L.

AU - Barrow, Robert E.

AU - Herndon, David

PY - 2004/7

Y1 - 2004/7

N2 - The hypercatabolism after massive pediatric burns has been effectively treated with recombinant human growth hormone, an anabolic agent that stimulates protein synthesis and abrogates growth arrest. While experimental studies have shown increased potential for fibrosis induced by growth hormone therapy, adverse effects on human scars have not been investigated. Our aim was to evaluate hypertrophic scar formation in 62 patients randomized to receive injections of 0.05mg/kg/day of recombinant human growth hormone or placebo, from discharge until 1 year after burn. Scar scales were used to evaluate scar-severity at discharge, 6, 9, 12, and 18-24 months after burn, by three observers blinded to treatment. Computer-assisted planimetry allowed quantification of percentage of hypertrophic scar formation. Types I and III collagens were localized and quantified in scars and normal skin of patients from both groups, using immunohistochemistry with confocal laser microscopy analysis. Insulin-like growth factor-1 blood levels helped assess compliance. Statistical analysis showed that scar hypertrophy significantly increased from 6 to 12 months after injury in both groups, while decreasing at 18-24 months postburn. Types I and III collagens were statistically increased in the reticular layer of scars from both groups when compared to paired normal skin. Insulin-like growth factor-1 was significantly increased in the recombinant human growth factor-treated group. No differences were seen when recombinant human growth factor and control groups were compared using the scar scales, planimetry, or immunohistochemistry. We concluded that recombinant human growth hormone therapy did not adversely affect scar formation and should not contraindicate the administration of recombinant human growth hormone as a therapeutic approach to severely burned children.

AB - The hypercatabolism after massive pediatric burns has been effectively treated with recombinant human growth hormone, an anabolic agent that stimulates protein synthesis and abrogates growth arrest. While experimental studies have shown increased potential for fibrosis induced by growth hormone therapy, adverse effects on human scars have not been investigated. Our aim was to evaluate hypertrophic scar formation in 62 patients randomized to receive injections of 0.05mg/kg/day of recombinant human growth hormone or placebo, from discharge until 1 year after burn. Scar scales were used to evaluate scar-severity at discharge, 6, 9, 12, and 18-24 months after burn, by three observers blinded to treatment. Computer-assisted planimetry allowed quantification of percentage of hypertrophic scar formation. Types I and III collagens were localized and quantified in scars and normal skin of patients from both groups, using immunohistochemistry with confocal laser microscopy analysis. Insulin-like growth factor-1 blood levels helped assess compliance. Statistical analysis showed that scar hypertrophy significantly increased from 6 to 12 months after injury in both groups, while decreasing at 18-24 months postburn. Types I and III collagens were statistically increased in the reticular layer of scars from both groups when compared to paired normal skin. Insulin-like growth factor-1 was significantly increased in the recombinant human growth factor-treated group. No differences were seen when recombinant human growth factor and control groups were compared using the scar scales, planimetry, or immunohistochemistry. We concluded that recombinant human growth hormone therapy did not adversely affect scar formation and should not contraindicate the administration of recombinant human growth hormone as a therapeutic approach to severely burned children.

UR - http://www.scopus.com/inward/record.url?scp=3442878380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442878380&partnerID=8YFLogxK

U2 - 10.1111/j.1067-1927.2004.012407.x

DO - 10.1111/j.1067-1927.2004.012407.x

M3 - Article

C2 - 15260805

AN - SCOPUS:3442878380

VL - 12

SP - 404

EP - 411

JO - Wound Repair and Regeneration

JF - Wound Repair and Regeneration

SN - 1067-1927

IS - 4

ER -